<DOC>
	<DOC>NCT01789281</DOC>
	<brief_summary>Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator</brief_summary>
	<brief_title>Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Patient is currently enrolled in a Novartissponsored, CD&amp;MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent study Patient is currently benefiting from treatment with everolimus, as determined by the guidelines of the parent protocol. Patient has been permanently discontinued from everolimus study treatment in the parent study. Patient is receiving everolimus in combination with an unapproved or experimental treatment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoplasms, Carcinoid tumor, Neuroendocrine tumor</keyword>
</DOC>